Almac IXRS 3 vs Suvoda RTSM(RTSM / IRT)

Sponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.

Scope Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.

Guide updated How we compare

Compare within RTSM / IRT

Study fit, side by side

These notes describe the products in the RTSM / IRT guide.

Almac IXRS 3

Best for
Sponsors who also use Almac for clinical packaging and distribution and want IRT, forecasting and logistics from one group
What to consider
Almac's IXRS 3 links to Almac's own clinical supply, SupplyWise forecasting and distribution services, and supports direct-to-patient workflows. Almac reports about 2,000 trials run on IXRS. Its public pages give no build timeline, name few randomization methods and show no named security certification.
Read product profile

Suvoda RTSM

Best for
Oncology, CNS and rare disease sponsors who want IRT alongside eCOA, eConsent and patient payments on one platform
What to consider
Suvoda runs its RTSM on one platform with eCOA, eConsent and Greenphire patient payments, and offers pre-built API integrations with major EDCs. It publishes the shortest build claim on this list (kickoff to UAT in as little as two weeks, footnoted as preliminary testing) and an annual SOC 2 Type 2 audit for RTSM. Its public pages name stratification and adaptive designs but not minimization.
Read product profile

Compare the features

Both products use the same category definitions. Product order is editorial; products are not ranked.

Full RTSM / IRT feature comparison

Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.

Expand a feature definition or support note for context and its original source.

Almac IXRS 3 vs Suvoda RTSM (RTSM / IRT): category feature evidence and sources. Products are not ranked.
Category featureAlmac IXRS 3Suvoda RTSM
Randomization and blinding
Feature definitions
Supported
Randomization or blinding workflows are stated.
Extended support
Named allocation methods include minimization or dynamic allocation.
Supported

Almac describes simple to complex adaptive designs with enrollment caps, cohorts and blinding protection, but does not name allocation methods.

Source
About this support label

Adaptive designs and blinding protection establish base support; allocation methods are not named.

Supported

Suvoda lists adaptive randomization, stratification, cohort and dose management and blinding management, but its public pages do not name minimization or dynamic allocation.

Source
About this support label

Adaptive and stratified randomization are stated; minimization or dynamic allocation is not named.

Trial supply management
Feature definitions
Supported
Drug inventory, dispensing, shipping or resupply workflows are documented.
Extended support
Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Extended support

IXRS 3 documents resupply strategy, expiry and depot management, Almac's SupplyWise integrates demand forecasting with the IRT, and an Almac datasheet (Clinical Leader, August 2025) describes direct-to-patient workflows.

Source
About this support label

Resupply and SupplyWise forecasting combine with documented direct-to-patient workflows.

Extended support

The RTSM page lists drug supply forecasting, direct-to-patient shipping, temperature excursion management, and accountability, returns and destruction.

Source
About this support label

Drug forecasting and direct-to-patient shipping are both named.

Study build speed and mid-study changes
Feature definitions
Supported
Study setup or post-go-live study changes are described.
Extended support
Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Supported

Almac describes a controlled-agile build with visual requirements tools, but publishes no build timeline or mid-study change process.

Source
About this support label

Visual study build is described; a build timeline and mid-study change process are not published.

Supported

Suvoda states kickoff to UAT in as little as two weeks (footnoted as preliminary testing), and permissioned users can make common post-go-live changes without a change order.

Source
About this support label

The UAT timeline concerns preliminary testing; permissioned changes do not establish uninterrupted live use.

Integrations and platform
Feature definitions
Supported
Integration or data exchange with another system or application is described.
Extended support
Integration with a clinical-trial application plus an API for integration are both stated.
Extended support

Almac lists pre-built connectors and REST, SOAP and secure file integrations with EDC, CTMS, clinical supplies and central labs, but has no EDC or eCOA of its own.

Source
About this support label

EDC/CTMS connectors are documented with REST and SOAP integrations.

Extended support

Suvoda reports integrations with more than 100 eClinical systems, standardized pre-built API integrations with top EDC providers and a REST API.

Source
About this support label

Pre-built EDC API integrations and a REST API are stated.

Compliance and security evidence
Feature definitions
Supported
Relevant trial compliance or security controls are stated, with their scope identified.
Extended support
Relevant trial controls and a publicly accessible ISO certificate or SOC audit report covering the product or vendor are documented.
Supported

Almac states its IXRS University training module is validated and 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation for Clinical Technologies.

Source
About this support label

The Part 11 statement is limited to IXRS University training; ISO/SOC evidence was not found.

Supported

Suvoda says its RTSM adheres to 21 CFR Part 11 and that it maintains SOC 2 Type 2 compliance; its certifications page confirms an annual SOC 2 Type 2 audit for RTSM.

Source
About this support label

RTSM trial controls and an annual SOC audit are stated; public report access is not established.

Track record
Feature definitions
Supported
Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support
Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Extended support

Almac's media kit reports 2,000 clinical trials and over 2 million patients on IXRS, in more than 85 countries (undated kit).

Source
About this support label

Product-specific trial and patient figures are reported across a stated country count.

Extended support

Suvoda reports 6,000+ trials and 115+ countries supported.

Source
About this support label

Product-specific trial adoption is reported across a stated country count.

The guide update date reflects guide edits. Vendor statements are attributed in the evidence.

Keep the category in view

Compare these products with the other tools in the RTSM / IRT guide using the same feature definitions.

More RTSM / IRT comparisons featuring one of these products.